Novelli et al. Upadacitinib in male vs female PsA. Data from SELECT-PsA studies. Appears equivalent in males and females, contrasting with TNFi/IL17i data. @RheumNow #ACR25 Abstr#557 https://t.co/fMKsbCkju0

In a novel Geri-Rheum clinic, cognitive screening revealed 35% impairment among adults >55 yrs. Common deficits: visuospatial, attention & recall. Early geriatric screening = earlier intervention. A model for age-friendly rheum care in action. @RheumNow #ACR25 Abstract #0226 https://t.co/lIAcrZvL4H

Heydari-Kamjani et al. Risk of DILI with avacopan. Real world study, propensity score matching. Risk DILI 2% with avacopan vs 1.9% PBO @RheumNow #ACR25 Abstr#724 https://t.co/UhVkcXEYjF

Ogdie et al. Week 24 results of SOLSTICE study. Guselkumab in TNF-IR in PsA. Good efficacy on skin and joint disease. No difference seen in Q4 vs Q8 weekly doses. @RheumNow #ACR25 Abstr#563 https://t.co/ztK0O9iKb8

Observational study of fibrinogen for diagnosis of GCA At a cutoff of 4.7, roughly similar diagnostic performance as compared to ESR/CRP Kind of neat, but does not appear to have additive benefit #ACR25 @RheumNow Abstr#0750 https://t.co/xy2qn4jHXP

ILD found in 30% of Sjögren’s pts w/ HRCT. A new nomogram-based tool (AUC 0.8) predicts ILD risk using age, ESR, C3, hypergammaglobulinemia & anti-La/SSB. Goal: guide HRCT referrals & catch ILD earlier. @RheumNow #ACR25 Abstract #0510 https://t.co/FvAprq8eol

2-Year data from SELECT-GCA Phase 3 UPA in GCA Re-randomization & 52 weeks extension UPA 15mg vs. PBO -Risk of flare 90% lower -Complete remission 70% vs 20% -Cumulative GC 1g difference -No new safety signal The quick relapse after stopping UPA indicates we are really looking https://t.co/c1khywnPNv

Immune-Mediated Necrotizing Myopathy @EleniTiniakou #ACR25 *Younger pts tend to have a more aggressive disease *IVIG and RTX can be considered first-line rx for anti-HMGCR and anti-SRP+, respectively *CYC and plasmapheresis may be options in cases of aggressive disease https://t.co/zWDX79gqlf

Real world effectiveness of voclosporin for SLE Reduction in UPCR from 2.1 at b/l to 0.9 at 6 months, no improvement in eGFR; as expected based on trials Wonder about market share of BEL vs voclo vs ANI - anyone seen pubs on this? #ACR25 @RheumNow Abstr#0661 https://t.co/l7i7IWhLSe

#ACR25 Abstr#775 Previous study showed plasma tRNA-derived RNA (tDR-1), produced by bacteria from the phylum Proteobacteria, was assoc. with lower RA activity. In 60 At-Risk CCP3+ people, Plasma tDR-1 improved prediction of RA. Need validation & adoption in practice @RheumNow https://t.co/XBmtohBEHc

From the FOREMOST study factors predicting progression from oligo to polyarticular PsA: Female sex, enthesitis and dactylitis found to increase the risk of progression. Among patients in FOREMOST receiving PBO, prior csDMARD use was protective. Abstract#0576 @RheumNow #ACR25 https://t.co/CFMhAFgFBa